BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Karnsakul W, Wasuwanich P, Ingviya T, Vasilescu A, Carson KA, Mogayzel PJ, Schwarz KB. A longitudinal assessment of non-invasive biomarkers to diagnose and predict cystic fibrosis-associated liver disease.J Cyst Fibros. 2020;19:546-552. [PMID: 32482593 DOI: 10.1016/j.jcf.2020.05.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Calvopina DA, Lewindon PJ, Ramm LE, Noble C, Hartel GF, Leung DH, Ramm GA. Gamma-glutamyl transpeptidase-to-platelet ratio as a biomarker of liver disease and hepatic fibrosis severity in paediatric Cystic Fibrosis. J Cyst Fibros 2021:S1569-1993(21)02171-8. [PMID: 34953741 DOI: 10.1016/j.jcf.2021.10.014] [Reference Citation Analysis]
2 Tosco A, Sepe A, Castaldo A, Catzola A, Cimbalo C, Angelini V, Vallone G, Buzzetti R, Raia V, Caprio MG. Non-invasive tools for detection of liver disease in children and adolescents with cystic fibrosis. Transl Pediatr 2021;10:2952-9. [PMID: 34976761 DOI: 10.21037/tp-21-68] [Reference Citation Analysis]
3 Konrad J, Eber E, Stadlbauer V. Changing paradigms in the treatment of gastrointestinal complications of cystic fibrosis in the era of cystic fibrosis transmembrane conductance regulator modulators. Paediatr Respir Rev 2020:S1526-0542(20)30181-0. [PMID: 33485777 DOI: 10.1016/j.prrv.2020.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Hoskins B, Wasuwanich P, Scheimann AO, Karnsakul W. Screening strategy for gastrointestinal and hepatopancreatobiliary cancers in cystic fibrosis. World J Gastrointest Oncol 2021; 13(9): 1121-1131 [PMID: 34616517 DOI: 10.4251/wjgo.v13.i9.1121] [Reference Citation Analysis]
5 Scott J, Jones AM, Piper Hanley K, Athwal VS. Review article: epidemiology, pathogenesis and management of liver disease in adults with cystic fibrosis. Aliment Pharmacol Ther 2022. [PMID: 35048397 DOI: 10.1111/apt.16749] [Reference Citation Analysis]
6 Sathe M, Sharma PB, Savant AP. Year in review 2020: Nutrition and gastrointestinal disease in cystic fibrosis. Pediatr Pulmonol 2021. [PMID: 34310872 DOI: 10.1002/ppul.25587] [Reference Citation Analysis]
7 Sellers ZM. Barrier to using APRI and GPR as identifiers of cystic fibrosis liver disease. J Cyst Fibros 2021;20:551. [PMID: 32747194 DOI: 10.1016/j.jcf.2020.07.018] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Athwal VS, Scott JA, Fitzpatrick E, Rowland M. Emerging clinical perspectives in cystic fibrosis liver disease. Curr Opin Pulm Med 2021;27:593-9. [PMID: 34482340 DOI: 10.1097/MCP.0000000000000824] [Reference Citation Analysis]